VIA Pharmaceuticals, Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Boehringer Ingelheim Taps In

Enter another competitor in the already crowded NASH arena: troubled oncology firm Synta Pharmaceuticals Corp. and privately held Madrigal Pharmaceuticals Inc. are merging in an all-stock deal

Paladin Labs, the Canadian speciality pharmaceutical company, is expanding its reach into the sub-Saharan pharmaceuticals market by acquiring all the Pharmaplan shares it does not already hold and the

As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They’re not put off by recent high-profile setbacks, given the huge remaining unmet need and commerci